Sanara MedTech Inc.

What they do

Sanara develops and commercializes surgical products for use in operating rooms, focusing on soft tissue repair and bone fusion. Its lead products include CellerateRX Surgical Powder (hydrolyzed collagen for wound management), BIASURGE (surgical irrigation solution), and bone fusion products such as BiFORM and ALLOCYTE Plus. It also has an in-house R&D team, Rochal Technologies, and markets products to hospitals and surgical centers.

Revenue drivers

• Soft tissue repair products — Largest revenue stream; includes CellerateRX Surgical, BIASURGE, and TEXAGEN. In Q2 2026, generated $25.2 million (90% of total net revenue).
• Bone fusion products — Includes BiFORM and ALLOCYTE Plus. Q2 2026 revenue was $2.9 million (10% of total net revenue).

Recent performance

In Q2 2026, net revenue rose 9% year-over-year to $28.1 million, with gross profit at 93% of revenue. Operating income was $1.8 million, down from $2.5 million, and net loss from continuing operations was $0.4 million vs. income of $0.5 million in Q2 2025. For the first half of 2026, revenue increased 14% to $55.9 million and Adjusted EBITDA was $9.3 million. Cash and equivalents were $15.4 million with long-term debt of $46.5 million at June 30, 2026.

Strategy

Sanara has discontinued its value-based wound care program (THP) to focus exclusively on surgical products. Management is expanding its distributor relationships and preparing to launch OsStic, a synthetic injectable bone void filler, in Q1 2027. The company has agreed to be acquired by MiMedx Group, a transaction expected to combine Sanara's surgical portfolio with MiMedx's wound care and surgical offerings.

Risks

• History of losses — The company has had a history of net losses (including 2021, 2022, and 2024) and may continue to incur losses as it expands selling efforts.
• Debt covenants — Outstanding indebtedness includes financial and operating covenants that restrict business activities and could affect cash flow.
• Dependence on license agreements — Revenue from certain products relies on license agreements with manufacturers; termination could harm the business.
• Merger completion risk — The proposed acquisition by MiMedx is subject to customary closing conditions and may not be completed, causing uncertainty.

Outlook

Management expects continued revenue growth and gross margin expansion, with OsStic launch anticipated in Q1 2027. The company is also focused on completing the MiMedx merger, which is expected to create a leading regenerative medicine company. Further detail on full-year guidance was not provided in the supplied materials.